VEGF proteins in human body induce the formation of new blood vessels and thus, help in the tissue growth. However, in certain cases like macular degeneration process, the VEGF causes abnormal blood vessels formation that leads to vision loss. Anti-VEGF medicines or injections work by inhibiting the activation of VEGF receptors. Recent findings suggest the better outcomes and clinical benefits of anti-VEGF medicines in macular degeneration.
However, using these medicines in Indian patients pose some challenges such as patient preference, health insurance coverage, the difference in fractionation and injection techniques, and absence of compounding pharmacies etc. Given the benefits of these medicines, How can physicians counsel the Indian patients about the benefits of this therapy? According to you, what are the challenges of using anti-VEGF medicines in the Indian context? American…
